Dioseve is a biotechnology company building an iPS cell-based platform to reliably produce human oocytes and ovarian somatic cells, aiming to address some of the most persistent medical and societal challenges around fertility and pregnancy. By turning advanced stem cell biology into a practical toolset for reproductive medicine, Dioseve is creating new options that lessen the impact on patients and improve success rates.

Its first product, DIOS-101 is an in vitro maturation approach that matures eggs ex vivo in an engineered ovarian‑like environment, with the goal of reducing hormone burden and clinic visits.